Journey Medical Corporation (DERM) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Journey Medical Corporation (DERM) Healthcare & Pipeline Overview

Journey Medical Corporation (DERM) develops and commercializes pharmaceutical products for dermatological conditions in the U.S., including treatments for hyperhidrosis and acne. With a market capitalization of $206M, the company focuses on specialty and generic drugs within the healthcare sector, operating with a gross margin of 59.3%.

What Is the Investment Thesis for DERM?

Journey Medical Corporation presents a focused investment opportunity within the specialty dermatology pharmaceutical market. The company's established portfolio of branded and generic products, including Qbrexza and Accutane, provides a revenue base. With a market capitalization of $206M and a gross margin of 59.3%, Journey Medical demonstrates potential for profitability, despite a current profit margin of -18.5%. Growth catalysts include expanding the market reach of existing products and potential acquisitions of complementary dermatological assets. However, investors may want to evaluate the risks associated with pharmaceutical development, regulatory hurdles, and competition within the dermatology market. The company's beta of 1.04 indicates market-correlated volatility.

Based on FMP financials and quantitative analysis

DERM Key Highlights

Market capitalization of $206M, reflecting the company's current valuation in the market.

• Gross margin of 59.3%, indicating strong profitability on product sales before operating expenses.
• Profit margin of -18.5%, highlighting current challenges in achieving overall profitability.
• Beta of 1.04, suggesting the stock's price movements are generally in line with the overall market.
• Focus on dermatological conditions, positioning the company in a specialized and potentially high-growth market segment.

Who Are DERM's Competitors?

DERM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are DERM's Key Strengths?

Specialized focus on dermatological products.

• Established portfolio of branded and generic medications.
• Existing distribution network within the United States.
• Proprietary products like Qbrexza for hyperhidrosis.

What Are DERM's Weaknesses?

Relatively small size compared to larger pharmaceutical companies.

• Dependence on a limited number of key products.
• Negative profit margin indicating current financial challenges.
• Limited geographic diversification, focused primarily on the U.S. market.

What Could Drive DERM Stock Higher?

Potential FDA approval for new dermatological products in development.

• Expansion of the sales and marketing efforts for Qbrexza.
• Strategic acquisitions of complementary dermatological assets.

What Are the Key Risks for DERM?

Financial-distress signal — its Altman Z-Score of 1.16 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-35.6%) — the business is not currently generating profit on shareholder capital.
• Regulatory setbacks or delays in the approval of new products.
• Increased competition from generic competitors and larger pharmaceutical companies.
• Dependence on a limited number of key products for revenue generation.
• Challenges in achieving profitability due to high operating expenses.

What Are the Growth Opportunities for DERM?

• Expanding the Market Reach of Qbrexza: Qbrexza, a medicated cloth towelette for hyperhidrosis, holds significant growth potential through increased marketing and distribution efforts. The global hyperhidrosis treatment market is projected to reach $1.5 billion by 2028, presenting a substantial opportunity for Journey Medical. By targeting specific patient populations and expanding its sales channels, Journey Medical can capture a larger share of this growing market. This expansion could involve partnerships with dermatology clinics and online pharmacies to improve accessibility and awareness.
• Strategic Acquisitions of Complementary Products: Journey Medical can pursue strategic acquisitions of complementary dermatological products to broaden its portfolio and revenue streams. Identifying and acquiring products that address unmet needs in the dermatology market can enhance the company's competitive position. This strategy could involve acquiring smaller companies with innovative technologies or established products in niche markets. Successful integration of these acquisitions would drive revenue growth and create synergies within the existing business.
• Development of New Formulations and Delivery Systems: Investing in research and development to create new formulations and delivery systems for existing drugs can extend their market exclusivity and improve patient outcomes. For example, developing a longer-lasting or more convenient formulation of Accutane could enhance its appeal to patients and prescribers. This approach requires a commitment to innovation and a deep understanding of patient needs. Successful development and commercialization of new formulations would create a competitive advantage and drive long-term growth.
• Geographic Expansion into International Markets: While currently focused on the United States, Journey Medical can explore opportunities to expand into international markets. The global dermatology market is vast and diverse, with significant unmet needs in many regions. Conducting market research to identify promising international markets and establishing partnerships with local distributors can facilitate successful expansion. This strategy requires careful consideration of regulatory requirements and cultural differences, but it offers the potential for substantial revenue growth.
• Leveraging Telemedicine and Digital Health Platforms: Integrating telemedicine and digital health platforms into its marketing and sales strategies can enhance patient access and engagement. Telemedicine allows patients to consult with dermatologists remotely, increasing convenience and accessibility. By partnering with telemedicine providers and developing its own digital health tools, Journey Medical can reach a wider audience and improve patient adherence to its products. This approach aligns with the growing trend of digital health and offers a competitive advantage in the market.

What Threats Does DERM Face?

• Competition from larger pharmaceutical companies with greater resources.
• Regulatory challenges and potential changes in healthcare policies.
• Patent expirations and the entry of generic competitors.
• Potential product liability claims and recalls.

What Are DERM's Competitive Advantages?

• Established portfolio of branded and generic dermatological products.
• Specialized focus on specific dermatological conditions.
• Proprietary formulations and delivery systems for certain products.
• Strong relationships with dermatologists and other healthcare providers.

What Does DERM Do?

Journey Medical Corporation, originally incorporated as Coronado Dermatology, Inc. in 2014 and later rebranded, is a pharmaceutical company dedicated to the development and commercialization of dermatological products in the United States. Headquartered in Scottsdale, Arizona, the company addresses a range of skin conditions through its portfolio of prescription medications. Journey Medical's product line includes Qbrexza, a medicated cloth towelette designed to treat primary axillary hyperhidrosis (excessive underarm sweating). The company also offers Accutane, an oral isotretinoin medication for severe recalcitrant acne, and Targadox, an oral doxycycline drug used as adjunctive therapy for severe acne. Ximino, an oral minocycline drug, is another key product targeting moderate to severe acne. Additionally, Journey Medical provides Exelderm cream and solution for topical use, along with other dermatological products like doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution. These products are strategically aimed at capturing significant market share within the dermatology space, focusing on both common and severe skin conditions.

What Products and Services Does DERM Offer?

• Develop and commercialize pharmaceutical products.
• Focus on treatments for dermatological conditions.
• Market Qbrexza for primary axillary hyperhidrosis.
• Offer Accutane for severe recalcitrant acne.
• Provide Targadox as adjunctive therapy for severe acne.
• Sell Ximino for moderate to severe acne.
• Distribute Exelderm cream and solution for topical use.
• Offer doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.

How Does DERM Make Money?

• Develop and acquire pharmaceutical products for dermatological conditions.
• Manufacture or outsource the production of these products.
• Market and sell products through a network of healthcare providers and pharmacies.
• Generate revenue through product sales and licensing agreements.

What Industry Does DERM Operate In?

Journey Medical Corporation operates within the specialty dermatology pharmaceutical industry, a segment characterized by increasing demand for advanced treatments for various skin conditions. The market is driven by factors such as an aging population, rising awareness of skin health, and the availability of innovative therapies. Competition includes both large pharmaceutical companies with diverse portfolios and smaller, specialized players. Journey Medical's focus on specific dermatological conditions like hyperhidrosis and acne allows it to carve out a niche within this competitive landscape. The company's ability to effectively market and distribute its products will be crucial for success in this dynamic environment.

Who Are DERM's Key Customers?

• Patients with dermatological conditions such as hyperhidrosis and acne.
• Dermatologists and other healthcare providers who prescribe the company's products.
• Pharmacies that dispense the company's medications.
• Hospitals and clinics that use the company's products.

Company Profile

Journey Medical Corporation operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Scottsdale, US. The company is led by CEO Claude Maraoui. DERM has traded publicly since 2021.

Return on equity for Journey Medical Corporation stands at -35.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -10.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.72 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -5.0%, the inverse of the P/E and a quick read on earnings relative to price.

DERM Valuation & Market Position

With a $206M market cap, Journey Medical Corporation sits in the micro-cap segment of the market. Relative to its peer group, DERM's quantitative score of 33/100 is below the peer average of 65/100.

Quarterly Financial Performance: Journey Medical Corporation

Revenue for Journey Medical Corporation came in at $18.5M during Q2 2026, a 16.0% improvement versus the preceding quarter. The company recorded a net loss of $312K, with diluted EPS of $-0.01. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, DERM averaged $-0.06 in diluted EPS.

Journey Medical Corporation's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.16 places it in the distress zone, a signal of elevated financial risk.

Journey Medical Corporation has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 15.5% above estimates on average.

Wall Street analysts project Journey Medical Corporation revenue of about $82.6M for fiscal 2026, with EPS near $0.07. The estimate reflects 3 contributing analysts.

DERM Financials

DERM Latest News

DERM Analyst Consensus

DERM MoonshotScore

Common Questions About DERM (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources